Literature DB >> 27590791

Hepatitis C Drugs: Is Next Generation the Last Generation?

Jean-Michel Pawlotsky1.   

Abstract

Entities:  

Mesh：

Year:  2016        PMID： 27590791     DOI： 10.1053/j.gastro.2016.08.043

Source DB:  PubMed          Journal:  Gastroenterology        ISSN： 0016-5085            Impact factor:   22.682


× No keyword cloud information.
  10 in total

1.  Clinical development of hepatitis C virus host-targeting agents.

Authors:  Mirjam B Zeisel; Thomas F Baumert
Journal:  Lancet       Date:  2017-01-11       Impact factor: 79.321

2.  Hepatitis: MicroRNA antagonists: promising antiviral agents against HCV and other viruses?

Authors:  Jean-Michel Pawlotsky
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2017-03-15       Impact factor: 46.802

3.  HCV communication within ego-centric networks of men and women who inject drugs.

Authors:  Marisa Felsher; Karin E Tobin; Mark Sulkowski; Carl Latkin; Oluwaseun Falade-Nwulia
Journal:  Drug Alcohol Depend       Date:  2021-10-29       Impact factor: 4.492

4.  Acceptability of Patient-Reported Outcome and Experience Measures for Hepatitis C Treatment Among People Who Use Drugs.

Authors:  Annie Madden; Max Hopwood; Joanne Neale; Carla Treloar
Journal:  Patient       Date:  2019-04       Impact factor: 3.883

5.  Beyond cure: patient reported outcomes of hepatitis C treatment among people who inject drugs in Australia.

Authors:  Annie Madden; Max Hopwood; Joanne Neale; Carla Treloar
Journal:  Harm Reduct J       Date:  2018-08-15

6.  Beyond interferon side effects: What residual barriers exist to DAA hepatitis C treatment for people who inject drugs?

Authors:  Annie Madden; Max Hopwood; Joanne Neale; Carla Treloar
Journal:  PLoS One       Date:  2018-11-30       Impact factor: 3.240

7.  Adherence to pan-genotypic glecaprevir/pibrentasvir and efficacy in HCV-infected patients: A pooled analysis of clinical trials.

Authors:  Ashley Brown; Tania M Welzel; Brian Conway; Francesco Negro; Norbert Bräu; Jason Grebely; Massimo Puoti; Alessio Aghemo; Henning Kleine; David Pugatch; Federico J Mensa; Yaozhu J Chen; Yang Lei; Eric Lawitz; Tarik Asselah
Journal:  Liver Int       Date:  2019-10-18       Impact factor: 5.828

Review 8.  Status of Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection and Remaining Challenges.

Authors:  Thomas F Baumert; Thomas Berg; Joseph K Lim; David R Nelson
Journal:  Gastroenterology       Date:  2018-10-17       Impact factor: 33.883

Review 9.  What do clinicians need to watch for with direct-acting antiviral therapy?

Authors:  Alessio Aghemo; Lionel Piroth; Sanjay Bhagani
Journal:  J Int AIDS Soc       Date:  2018-04       Impact factor: 5.396

10.  Characterization of the Anti-Hepatitis C Virus Activity of New Nonpeptidic Small-Molecule Cyclophilin Inhibitors with the Potential for Broad Anti-Flaviviridae Activity.

Authors:  Quentin Nevers; Isaac Ruiz; Jean-Michel Pawlotsky; Abdelhakim Ahmed-Belkacem; Nazim Ahnou; Flora Donati; Rozenn Brillet; Laurent Softic; Maxime Chazal; Nolwenn Jouvenet; Slim Fourati; Camille Baudesson; Patrice Bruscella; Muriel Gelin; Jean-François Guichou
Journal:  Antimicrob Agents Chemother       Date:  2018-06-26       Impact factor: 5.191
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.